Smoking in patients receiving psychotrophic medications: A pharmacokinetic perspective

CNS Drugs

Volumn 15, Issue 6, 2001, Pages 469-494

  Desai, Hiral D ^a   Seabolt, Julia ^b   Jann, Michael W ^a  

^a MERCER UNIVERSITY   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; CHLORDIAZEPOXIDE; CHLORPROMAZINE; CLOMIPRAMINE; CLOZAPINE; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 2E1; DIAZEPAM; DOPAMINE; FLUPHENAZINE; FLUVOXAMINE; HALOPERIDOL; IMIPRAMINE; LORAZEPAM; NEUROLEPTIC AGENT; NICOTINE; NORTRIPTYLINE; OLANZAPINE; POLYCYCLIC AROMATIC COMPOUND; PSYCHOTROPIC AGENT; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; TIOTIXENE; TRAZODONE; TRIAZOLAM; TRIFLUOPERAZINE; VENLAFAXINE; ZOTEPINE;

DOPAMINERGIC SYSTEM; DRUG DISPOSITION; DRUG EFFECT; DRUG METABOLISM; DRUG UTILIZATION; HUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW; SMOKING;

EID: 0034958715     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200115060-00005     Document Type: Review

References (93)

1. Nicotine and caffeine abuse
2. Decreased concentration of phenacetin in plasma of cigarette smokers
3. Management of metabolic drug interactions
4. Biotransformation of xenobiotics
5. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians
6. Drug interactions with tobacco smoking
7. Inhibition and induction of human cytochrome P450 (CYP) enzymes
8. Human cytochromes P450: Problems and prospects
9. CYP 1A2 activity, gender, smoking as variables influencing the toxicity of caffeine
10. Functional significance of a C → A polymorphism in intron I of the cytochrome P 450 1A2 gene tested with caffeine
11. Enzyme induction in the cytochrome P450 system
12. Pharmacokinetic factors affecting antidepressant drug clearance and clinical effect: Evaluation of doxepin and imipramine - New data and review
13. Influence of cigarette smoking on drug metabolism in man
14. The significance of the effects of cigarette smoking on drug disposition
15. Pharmacokinetic changes in the elderly: Do they contribute to drug abuse and dependence?
16. Clinical implications of increased antipsychotic plasma concentrations upon anticonvulsant cessation
17. Clozapine drug-drug interactions: A review of the literature
18. Seizure following smoking cessation in a clozapine responder
19. How to help psychiatric patients stop smoking
20. Collaborative drug therapy management and smoking cessation
21. The relevance of ethnic influences on pharmacogenetics to the treatment of psychosis
22. Smoking and mental illness
23. Tricyclic plasma levels effects of age, race, sex, and smoking
24. Tricyclic plasma levels in depressed outpatients treated with amitriptyline
25. Cigarette smoking and plasma nortriptyline levels
26. Effect of alcohol consumption and cigarette smoking on antidepressant levels of depressed patients
27. Effects of smoking on nortriptyline plasma concentrations in depressed patients
28. Plasma levels of impramine in depression
29. Effects of age, cigarette smoking and the oral contraceptive on the pharmacokinetics clomipramine and its desmethyl metabolite during chronic dosing
30. Effect of cigarette smoking on fluvoxamine pharmacokinetics in humans
31. Effects of various factors on steady-state plasma concentrations of trazodone and its active metabolite m-chlorphenylpiperazine
32. Pharmacokinetics of bupropion and its metabolites in cigarette smokers versus nonsmokers
33. Imipramine blood levels and clinical outcome
34. Cigarettes and drug therapy: Pharmacokinetic and pharmacodynamic considerations
35. Influence of age, cigarette smoking and oral contraceptive on plasma concentrations of clomipramine
36. Clomipramine metabolism model-based analysis of variability factors from drug monitoring data
37. Metabolism of clomipramine in a Japanese psychiatric population: Hydroxylation, desmethylation, and glucuronidation
38. Effect of venlafaxine on CYP1A2-dependent pharmacokinetics and metabolism of caffeine
39. Differential prevalence of cigarette smoking in patients with schizophrenic vs mood disorders
40. Smoking, smoking withdrawal and schizophrenia: Case reports and a review of the literature
41. Cigarette smoking is associated with abnormal involuntary movements in the general male population - A study of men born in 1933
42. Smoker need higher doses of neuroleptic drugs
43. Effect of smoking on neuroleptics in schizophrenia
44. Drowsiness due to chlorpromazine in relation to cigarette smoking
45. Chlorpromazine plasma levels, adverse effects, and tobacco smoking: Case report
46. Cigarette smoking and chlorpromazine disposition and actions
47. Smoking and body weight influence the clearance of chlorpromazine
48. Thiothixene pharmacokinetics interactions: A study of hepatic enzyme inducers, clearance inhibitors, and demographic variables
49. Effects of smoking on fluphenazine clearance in psychiatric inpatients
50. Effects of smoking on haloperidol and reduced haloperidol plasma concentrations and haloperidol clearance
51. The influence of cigarette smoking on haloperidol pharmacokinetics
52. Haloperidol dosing requirements: The contribution of smoking and nonlinear pharmacokinetics
53. A pharmacokinetic study of trifluoperazine in two ethnic populations
54. Intersubject variation in the pharmacokinetics of haloperidol and reduced haloperidol
55. Haloperidol decanoate pharmacokinetics in red blood cells and plasma
56. Disposition of clozapine in man: Lack of association with debrisoquine and S-mephenytoin hydroxylation polymorphism
57. Olanzapine pharmacokinetic and pharmacodynamic profile
58. Possible inhibitory effect of diazepam on the metabolism of zotepine, an antipsychotic drug
59. Influence of patient-related variables on clozapine plasma levels
60. Relationship between clinical efficacy and clozapine concentrations in plasma in schizophrenia: Effect of smoking
61. Pharmacokinetic interaction of clozapine with selective serotonin reuptake inhibitors: Differential effects of fluvoxamine and paroxetine in a prospective study
62. Pharmacokinetics and pharmacodynamics of clozapine
63. Steady-state serum kinetics of zotepine
64. Therapeutic drug monitoring of risperidone using a new rapid HPLC method: Reappraisal of interindividual variability factors
65. Lack of influence of cigarette smoking on triazolam pharmacokinetics
66. Relationship between single oral dose pharmacokinetics of alprazolam and triazolam
67. Nonlinear mixed effects modeling of single dose and multiple dose data for an immediate release (IR) and a controlled released (CR) dosage form of alprazolam
68. Lorazepam kinetics in the elderly
69. Kinetics of diazepam, midazolam, and lorazepam in cigarette smokers
70. Diazepam disposition determinants
71. Pharmacokinetics of N-desmethyldiazepam after a single oral dose of clorazepate: The effect of smoking
72. Influence of propranolol coadministration on cigarette smoking on the kinetics of desmethyldiazepam following intravenous clorazepate
73. No effect of smoking on the metabolism of chlordiazepoxide
74. Clinical depression of the central nervous system due to diazepam and chlordiazepoxide in the relation to cigarette smoking and age
75. Effects of smoking on drug action
76. The effects of age and liver disease on the disposition and elimination of diazepam in adult man
77. Recent developments in the study of the effects of cigarette smoking on clinical pharmacokinetics and clinical pharmacodynamics
78. Antiepileptic drug pharmacokinetics and interactions: Impact on treatment of epilepsy
79. Absence of effect of cigarette smoking on serum concentrations of some anticon vulsants in epileptic patients
80. Postinduction carbamaz epine clearance in an adult psychiatric population
81. Lithium
82. Pathophysiology of tobacco dependence
83. Dopaminergic mechanisms in the locomotor stimulant effects of nicotine
84. Apparent tolerance to the acute effect of nicotine results in part from distribution kinetics
85. A physiologically based pharmacokinetic model for nicotine and cotinine in man
86. Nicotine and cotinine elimination pharmacokinetics in smokers and nonsmokers
87. Nicotine potentiates haloperidol induced catalepsy and locomotor hypoactivity
88. Nicotine potentiation of haloperidol in reducing tic frequency in Tourette's disorder
89. Smoking and tardive dyskinesia
90. Hypothesis: A nicotine-dopamine interaction linking smoking with Parkinson's disease and tardive dyskinesia
91. Smoking and movement disorders in psychiatric patients
92. A functional polymorphism of the cytochrome P450 1A2 gene: Association with tardive dyskinesia in schizophrenia